Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

  • J Med Chem. 1999 Apr 8;42(7):1203-12. doi: 10.1021/jm980537b.
P S Dragovich  1 ,  T J Prins ,  R Zhou ,  S A Fuhrman ,  A K Patick ,  D A Matthews ,  C E Ford ,  J W Meador 3rd ,  R A Ferre ,  S T Worland
Affiliations
  • 1. Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121, USA.
Abstract

The structure-based design, Chemical Synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C Protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The ketomethylene-containing inhibitors typically display slightly reduced 3CP inhibition activity relative to the corresponding peptide-derived molecules, but they also exhibit significantly improved Antiviral properties. Optimization of the ketomethylene-containing compounds is shown to provide several highly active 3C Protease Inhibitors which function as potent antirhinoviral agents (EC90 = <1 microM) against multiple virus serotypes in Cell Culture.

Products